⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNTH News
Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
DNTH
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight
globenewswire.com
NVS
DNTH
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
DNTH
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
globenewswire.com
DNTH
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
globenewswire.com
DNTH
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
globenewswire.com
DNTH
Dianthus Therapeutics to Participate in Four Investor Conferences During November
globenewswire.com
DNTH
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
globenewswire.com
DNTH
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
globenewswire.com
DNTH
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
globenewswire.com
DNTH